NCT00578201View on ClinicalTrials.gov

FOLFOX-Cetuximab-radiotherapy for the Treatment of Esophageal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

February 28, 2011

Study Completion Date

February 28, 2011

Conditions
Esophageal Cancer Stage III
Interventions
DRUG

radiochemotherapy,combination Cetuximab-FOLFOX

objective response rate at 12 weeks with radiochemotherapy then combination Cetuximab-FOLFOX

Trial Locations (1)

69008

Clinique Saint Jean, Lyon

All Listed Sponsors
collaborator

GERCOR - Multidisciplinary Oncology Cooperative Group

OTHER

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT00578201 - FOLFOX-Cetuximab-radiotherapy for the Treatment of Esophageal Cancer | Biotech Hunter | Biotech Hunter